Pennap, Grace RinmecitVictor, Oti B.Aliribe, Gloria A.Abimiku, Ajegena S.Galleh, Raphael Peter2023-12-142023-12-142017-06-13Galleh, R.P. et al. (2017) Seroprevalence of Hepatitis B and C Viruses among Human Immunodeficiency Virus Infected Patients Accessing Healthcare in Federal Medical Centre, Keffi, Nigeriahttps://keffi.nsuk.edu.ng/handle/20.500.14448/5943nfections of Hepatitis B and C viruses among seropositive Human immunodeficiency virus patients are a growing public health problem in Sub Saharan Africa characterized by unaffordable treatment, severe morbidity and associated mortality. This study was aimed at evaluating the seroprevalence of Hepatitis B and C viruses among HIV infected patients accessing health care at Federal Medical Centre, Keffi, Nigeria. The cross-sectional study took place between May-July 2016. A total of 200 blood samples were collected from HIV patients after informed consent and self-administered questionnaires were completed. The samples were centrifuged and the serum screened for HBV and HCV using the immunochromatographic technique. A general prevalence of infection with hepatitis B and C viruses in the study population was 17.5%. The prevalence of HBV infection was 12.5% while HCV was 5.0%. Females have higher infection rates for both viruses (p > 0.05). HBV infection was highest among those aged 20-29 years (14.3%) and lowest among those aged 30-39 years (6.5%). HCV infection was highest among those aged > 40 years (8.7%) and least among those aged 30-39 years (0.0%). Infection rates with blood transfusion, smoking habit, scarification marks and alcohol intake as risk factors were more for HBV than HCV (p > 0.05). The HIV/HBV and HIV/HCV coinfection prevalence of 12.5% and 5.0% respectively is a cause for concern. This finding underscores the urgent need for more proactive HBV immunization programs and screening of HIV patients for HBV and HCV before and even during antiretroviral therapy. Health education against these silent killers should also be advocated.enHBV; HCV; HIV; Keffi; seroprevalence.Article